Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 26.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ive Date”). In accordance with Instruction 2 to Item 5.02 of Form 8-K, the Company is filing this Amendment No. 1 to the |
| 30.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ber 31, 2023 as well as the matters discussed in Item 5.02, the text of which is set forth as Exhibit 99.1. Item 8.01. O |
| 30.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ive Date”). In accordance with Instruction 2 to Item 5.02 of Form 8-K, the Company is filing this Amendment No. 1 to the |
Stammdaten
HCA Healthcare, Inc., through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. It also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, the company operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. As of December 31, 2021, it operated 182 hospitals, including 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals; 125 freestanding surgery centers; and 21 freestanding endoscopy centers in 20 states and England. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Unternehmen & Branche
| Name | HCA Healthcare, Inc. |
|---|---|
| Ticker | HCA |
| CIK | 0000860730 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Care Facilities |
| SIC | 8062 · Services-General Medical & Surgical Hospitals, NEC |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 97,44 Mrd. USD |
| Beta | 1,37 |
| Dividendenrendite | 2,94 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 75,600,000,000 | 6,784,000,000 | 28.33 | 60,720,000,000 | -6,027,000,000 |
| 2025-09-30 | 10-Q | 19,161,000,000 | 1,643,000,000 | 6.96 | 59,747,000,000 | -5,335,000,000 |
| 2025-06-30 | 10-Q | 18,605,000,000 | 1,653,000,000 | 6.83 | 59,536,000,000 | -4,394,000,000 |
| 2025-03-31 | 10-Q | 18,321,000,000 | 1,610,000,000 | 6.45 | 59,798,000,000 | -3,519,000,000 |
| 2024-12-31 | 10-K | 70,603,000,000 | 5,760,000,000 | 22.00 | 59,513,000,000 | -2,499,000,000 |
| 2024-09-30 | 10-Q | 17,487,000,000 | 1,270,000,000 | 4.88 | 59,459,000,000 | -2,182,000,000 |
| 2024-06-30 | 10-Q | 17,492,000,000 | 1,461,000,000 | 5.53 | 57,379,000,000 | -1,600,000,000 |
| 2024-03-31 | 10-Q | 17,339,000,000 | 1,591,000,000 | 5.93 | 56,962,000,000 | -1,615,000,000 |
| 2023-12-31 | 10-K | 64,968,000,000 | 5,242,000,000 | 18.97 | 56,211,000,000 | -1,774,000,000 |
| 2023-09-30 | 10-Q | 16,213,000,000 | 1,079,000,000 | 3.91 | 54,589,000,000 | -2,477,000,000 |
| 2023-06-30 | 10-Q | 15,861,000,000 | 1,193,000,000 | 4.29 | 53,594,000,000 | -2,303,000,000 |
| 2023-03-31 | 10-Q | 15,591,000,000 | 1,363,000,000 | 4.85 | 52,711,000,000 | -2,495,000,000 |
| 2022-12-31 | 10-K | 60,233,000,000 | 5,643,000,000 | 19.15 | 52,438,000,000 | -2,767,000,000 |
| 2022-09-30 | 10-Q | 14,971,000,000 | 1,134,000,000 | 3.91 | 51,484,000,000 | -3,370,000,000 |
| 2022-06-30 | 10-Q | 14,820,000,000 | 1,155,000,000 | 3.90 | 51,584,000,000 | -3,680,000,000 |
| 2022-03-31 | 10-Q | 14,945,000,000 | 1,273,000,000 | 4.14 | 52,208,000,000 | -2,033,000,000 |
| 2021-12-31 | 10-K | 58,752,000,000 | 6,956,000,000 | 21.16 | 50,742,000,000 | -933,000,000 |
| 2021-09-30 | 10-Q | 15,276,000,000 | 2,269,000,000 | 7.00 | 49,562,000,000 | -695,000,000 |
| 2021-06-30 | 10-Q | 14,435,000,000 | 1,450,000,000 | 4.36 | 48,164,000,000 | -593,000,000 |
| 2021-03-31 | 10-Q | 13,977,000,000 | 1,423,000,000 | 4.14 | 47,277,000,000 | 247,000,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | McAlevey Michael R | Officer, EVP & Chief Legal & Admin Off. | Open Market Sale | -1,694 | 533.37 | -903,536.74 | -35,2% | |
| 2026-02-11 | Wyatt Christopher F. | Officer, SVP & Controller | Open Market Sale | -4,000 | 505.00 | -2,020,000.00 | -78,6% | |
| 2026-02-11 | Berres Jennifer | Officer, SVP & Chief Human Res. Officer | Open Market Sale | -4,010 | 526.16 | -2,109,920.05 | -82,1% | |
| 2026-02-11 | Berres Jennifer | Officer, SVP & Chief Human Res. Officer | Open Market Sale | -4,010 | 503.00 | -2,017,030.00 | -78,5% | |
| 2026-02-03 | HAZEN SAMUEL N | Director, Officer, CEO | Open Market Sale | -5,162 | 498.80 | -2,574,793.73 | -100,2% | |
| 2026-02-03 | HAZEN SAMUEL N | Director, Officer, CEO | Open Market Sale | -7,395 | 500.69 | -3,702,626.21 | -144,1% | |
| 2026-02-03 | HAZEN SAMUEL N | Director, Officer, CEO | Open Market Sale | -14,716 | 502.95 | -7,401,385.71 | -288,1% | |
| 2026-02-03 | Cuffe Michael S. | Officer, EVP and Chief Clinical Officer | Open Market Sale | -1,500 | 498.09 | -747,135.15 | -29,1% | |
| 2026-02-03 | HAZEN SAMUEL N | Director, Officer, CEO | Open Market Sale | -6,189 | 500.02 | -3,094,608.93 | -120,5% | |
| 2026-02-03 | HAZEN SAMUEL N | Director, Officer, CEO | Open Market Sale | -120 | 497.18 | -59,661.40 | -2,3% | |
| 2026-02-03 | HAZEN SAMUEL N | Director, Officer, CEO | Open Market Sale | -4,293 | 498.12 | -2,138,442.04 | -83,3% | |
| 2026-02-03 | HAZEN SAMUEL N | Director, Officer, CEO | Open Market Sale | -5,002 | 502.15 | -2,511,756.80 | -97,8% | |
| 2025-11-05 | McAlevey Michael R | Officer, EVP & Chief Legal & Admin Off. | Open Market Sale | -3,892 | 473.79 | -1,843,990.68 | -71,8% | |
| 2025-09-08 | Cuffe Michael S. | Officer, EVP and Chief Clinical Officer | Open Market Sale | -3,836 | 418.84 | -1,606,670.24 | -62,6% | |
| 2025-05-13 | Foster Jon M | Officer, EVP and COO | Open Market Sale | -15,698 | 369.32 | -5,797,660.71 | -225,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.